About Arecor
Arecor is a company based in Cambridge (United Kingdom) founded in 2007. Arecor has raised $16.27 million across 5 funding rounds from investors including Gov.uk, Downing and Calculus Capital. Arecor has completed 1 acquisition, including Tetris Pharma. Arecor offers products and services including Arestat Technology and Enhanced Medicines. Arecor operates in a competitive market with competitors including Ensysce, Oxular, EryDel, PharmaJet and Splice Bio, among others.
- Headquarter Cambridge, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arecor Therapeutics Plc
-
Annual Revenue
$6.33 M (USD)10.5as on Dec 31, 2024
-
Net Profit
-$12.83 M (USD)-19.66as on Dec 31, 2024
-
EBITDA
-$8.83 M (USD)27.18as on Dec 31, 2024
-
Total Equity Funding
$16.27 M (USD)
in 5 rounds
-
Latest Funding Round
$8.26 M (USD), Series B
Jul 24, 2024
-
Investors
Gov.uk
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arecor
Arecor is a publicly listed company on the LSE with ticker symbol AREC in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arecor
Arecor offers a comprehensive portfolio of products and services, including Arestat Technology and Enhanced Medicines.
Platform for developing enhanced medicines for diabetes treatments.
Medicines targeting diabetes and obesity management through partnerships.
People of Arecor
Unlock access to complete
Unlock access to complete
Funding Insights of Arecor
Arecor has successfully raised a total of $16.27M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $8.26 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arecor
Arecor has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Downing and Calculus Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are managed by Albion Capital.
|
Locked | Locked | Locked | |
|
UK venture capital investments are managed by Calculus Capital.
|
Locked | Locked | Locked | |
|
Inheritance tax relief, funds, and bonds are provided across sectors.
|
Locked | Locked | Locked |
Investor details for Arecor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arecor
Arecor has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tetris Pharma.
Investment portfolio details for Arecor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Marketing services for healthcare products are provided by Tetris Pharma.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Arecor
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Arecor
Detailed financials for Arecor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arecor Comparisons
Peer comparison for Arecor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arecor
Arecor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ensysce, Oxular, EryDel, PharmaJet and Splice Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
Drug delivery platforms and therapeutics for ophthalmology are developed.
|
|
| Locked | Locked | Locked |
Erythrocyte encapsulation systems for drug delivery are developed.
|
|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Provider of a proprietary platform for gene therapy
|
Detailed competitors of Arecor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arecor
Complete news archive for Arecor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arecor
Arecor was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Arecor is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Arecor is a funded company, having raised a total of $16.27M across 5 funding rounds to date.
Annual revenue of Arecor is $6.33M as on Dec 31, 2024.
Arecor was founded in 2007 in Cambridge, United Kingdom, within the biotechnology sector. Stabilization technologies are utilized to formulate proteins and vaccines as stable aqueous or dry preparations, suitable for high concentrations or ionizing radiation exposure. The Arestat platform is integrated into existing manufacturing processes without covalent modifications to biologics, employing only GRAS excipients approved by regulatory authorities. Operations focus on enhancing drug delivery formulations.
Arecor's top competitors include Oxular, PharmaJet and Splice Bio.
Arecor offers Arestat Technology and Enhanced Medicines.
Yes, Arecor is publicly traded on LSE under the ticker symbol AREC.
Arecor has made 1 acquisition, including Tetris Pharma.
Arecor has 5 investors. Key investors include Gov.uk, Downing, Calculus Capital, Albion Capital, and Seneca Growth Capital.
The ticker symbol of Arecor is AREC on LSE.